Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review
Open accessThe DOI matches its Crossref record; 165 of the 167 references it cites were found in a registry or an index.
Abstract
As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces anti-tumor immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, and heat shock proteins. This leads to activation of tumor-specific immune responses, which can act in combination with the direct killing functions of chemotherapy drugs on cancer cells to further improve their curative effects. In this review, we highlight the molecular mechanisms underlying ICD, including those of several chemotherapeutic drugs in inducing DAMPs exposed during ICD to activate the immune system, as well as discussing the prospects for application and potential role of ICD in cancer immunotherapy, with the aim of providing valuable inspiration for future development of chemoimmunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite this, research suggests that immunogenic cell death (ICD) induced by chemotherapy, targeted therapy, and/or radiotherapy not only leads to cancer cell death but also stimulates anti-tumor immune responses through the release of tumor neoantigens and damage-associated molecular patterns (DAMPs) (Zhai et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Zhai et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Qu, L., Li, K., Liu, K., & Hu, W. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/4959840 · Cited by 2 · cited 1×
“mentioned that the treatment of gemcitabine and oxaliplatin combined with apatinib in gallbladder cancer will significantly increase the level of humoral immune cells, and significantly decrease the levels of sIL-2R, and sICAM-1 to effectively control the progress of the disease by improving the immune function (Qu et…”
BackgroundRetractedImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · cited 2×
“DAMPs, such as calreticulin (CRT), adenosine triphosphate (ATP), heat shock protein (HSP), and high mobility group box 1 (HMGB1) (Garg et al., 2010; Krysko et al., 2012; Boada-Romero et al., 2020).”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 4×
“Anthracyclines can trigger exposure to CRT, as well as HSP70 and HSP90 expression, which involves translocation of these markers to the cell surface, and thus induces anti-cancer immune responses and HMGB1 release (Obeid et al., 2007; Fucikova et al., 2011).”
BackgroundInfluentialChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 2×
“The recovery of GSDME expression in tumor cells is helpful to enhance the function of immune cells to inhibit tumor growth (Wang et al., 2017).”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 2×
“ICD is a form of regulated cell death typically driven by stress (Galluzzi et al., 2017), including cell stress and cell death accompanied by exposure, active secretion, or passive release of large numbers of OPEN ACCESS”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 5×
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574 · cited 1×
“Similarly, the mechanisms driving ICD have been used to produce DC-based tumor vaccines, and many clinical trials have been completed (Wculek et al., 2020).”
BackgroundMitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450 · cited 3×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101 · cited 1×
“First, ICD inducers must show superior therapeutic effect when used to treat tumors in mice with normal immune function compared with those with low immune function (Vesely et al., 2011; Garg et al., 2014; Kepp et al., 2014).”
Background
Cited by
Items 101–144 of 144
Pashaei, Y., Kulabaş, N., & Şenkardeş, S. (2026) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206429934251224112953 · Cited by 1
HMGB1 and HMGB2 proteins in ferroptosis, cancer, and neurodegeneration
Blair, I. A., Fan, J., & Liu, J. (2026) · Medical Research Archives · doi:10.18103/mra.v14i4.7401 · Cited by 1
Lv, C., Yu, H., Su, Y., Dai, X., Chen, J., Xu, T., & Dong, H. (2026) · Biofabrication · doi:10.1088/1758-5090/ae7b0a · Cited by 1
“Besides, antitumor drugs aimed at terminating the abnormal growth of tumor cells are variable, including targeted drugs, chemotherapy drugs, and immunotherapy drugs [3, 4].”
Zhu, Y., Li, Y., Jiang, Y., Fan, Z., & Liu, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00899 · Cited by 1
Self-citationLiu, Y., Zhang, L., Lei, X., Yin, X., & Liu, S. (2023) · Aging · doi:10.18632/aging.205132 · Cited by 1
“A growing number of preclinical and clinical evidence suggests that many successful antitumor therapies have benefited from the effective induction of ICD in tumor cells [17, 18].”
BackgroundSelf-citationPeng, W., Zhang, F., Ma, W., Da, J., Yu, H.-Q., Fan, L., Jia, Z., Xu, J., Gao, Z.-C., Shao, C., et al. (2025) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2025-189 · Cited by 1
“Preclinical models of other malignant diseases have shown that the addition of chemotherapy to combination treatment can strengthen the anti-tumor response elicited by ICIs by inducing immune-mediated cell death (12,13).”
Weissenstein, U., Tschumi, S., Leonhard, B., & Baumgartner, S. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04909-8 · Cited by 1
“The ICD-inducing chemotherapeutic taxol (paclitaxel) [30] and TM were used as positive controls.”
Chen, R., Ren, J., Wang, Y., Zhang, X., Jia, Y., Liu, C., & Qu, K. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01215-5
“This has far-reaching significance for antitumour therapy [25, 26].”
Song, Q., Zhou, Y. F., Li, M., Shi, C., & Pei, D. (2024) · Research Square · doi:10.21203/rs.3.rs-5276654/v1
Exploiting macropinocytosis for therapeutic intervention in RAS mutant Multiple MyelomaPreprint
Beals, N., Ramírez, C., Koide, A., Hauser, A. D., Davies, F. E., Koide, S., Morgan, G. J., & Bar‐Sagi, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647098
Chen, X., Yan, H.-P., Zhao, H., & Zhu, P. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1607715
“Potential mechanisms include: immunomodulatory effects through immunogenic cell death induction (17, 18) and MHC-I upregulation (19), radiosensitization properties via G2/M phase arrest (17, 20, 21), and metabolic advantages by avoiding fl uorouracil ’ s DPD de fi ciency risks.”
Swetha, M., Keerthana, C. K., Rayginia, T. P., Kalishwaralal, K., Shifana, S. C., Aiswarya, S. U. D., Nath, L. R., Varma, S. S., Viswanathan, A. (., Jannet, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.08.674785
“The chemotherapeutic effects of anti-cancer agents, coupled with their potential to induce ICD, culminates in sustained long-term therapeutic effects [12].”
Prasan, D., Raut, U., Madhumathi, H. K., Siddappa, G., Bonney, L. J., Suresh, A., & Dhar, S. K. (2025) · medRxiv · doi:10.1101/2025.09.23.25336416
“On the other hand, cytokines and chemokines also contribute to chemotherapy-induced immunogenic cell death (74).”
Chan, H. W., Tse, C. C. L., Li, Y.-C., Leung, R. C.-Y., Kwok, G. W., Wong, J. S. L., Li, K. H.-L., Tsang, J. W. Y., Li, C. W., Lo, J. W. Y., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01589-6
“It also induces immunogenic cell death, releasing tumour antigens to prime the immune system for pembrolizumab to activate T cells [16].”
Mathematical Modeling of Cellular Exhaustion to Guide Future Immunotherapy Research
Simmons, T. (2024) · University Libraries (University of Maryland) · doi:10.13016/kzjh-fle0 · Cited by 1
Silva, J. E. M. C. D. [. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The value of immunogenic cell death-related gene model in the prognosis of gastric cancer
Lang, Y., Wang, X.-Y., Liu, Z., Man, C., Gong, D., Zhang, S., Gao, Z., & Fan, Y. (2026) · Discover Oncology · doi:10.1007/s12672-025-04296-z
“Immunogenic chemotherapeutic drugs can induce ICD, and exert anti-tumor effects by mediating the release of DAMPs [6].”
Zhang, J., Zuo, Y., Sun, B., Wang, X., Tian, S., & Miao, M. (2026) · Antioxidants · doi:10.3390/antiox15030311 · Cited by 2
“Notably, drugs such as DOX, oxaliplatin (OXA), and paclitaxel are capable of inducing immunogenic cell death (ICD), a form of RCD that activates the adaptive immune system to mount a potent and specific anti-tumor response [167,168].”
Xu, R.-X., Guo, C., Chang, S., Men, X., Chen, C., & Luo, D. (2026) · The FASEB Journal · doi:10.1096/fj.202503735rr
Konishi, H., Yamashita, Y., Motomura, Y., Urai, S., Sasai, Y., Yamagami, K., Bando, H., & Kanamoto, N. (2026) · Endocrine Journal · doi:10.1507/endocrj.ej26-0108
“This form of cell death, which stimu‐ lates the immune system, is referred to as ICD [18].”
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
Ge, Q., Yu, L., Lu, J., Anwaier, A., Xiao, X., Chen, Y., Ye, D., Zhang, H., Xu, W., & Dai, W. (2026) · MedComm · doi:10.1002/mco2.70771 · Cited by 1
Wagoner, C. M. V., Kitelinger, L. E., DeWitt, M. R., Conarroe, C. A., Kim, A., Streit, A. B., Price, R. J., & Bullock, T. N. J. (2026) · Cells · doi:10.3390/cells15111035
“While anthracyclines like DOX are used as prototypic ICD-inducing agents [50–53,77 Similar to GEM and DOX, targeting Ly6G or Gr1 effectively depleted circulating neutrophils, with anti-Gr1 additionally reducing monocyte and inflammatory monocyte populations (Figure S8(A–Eii)) [41].”
From Innate Immunity to Cancer Therapy: Antimicrobial Peptides as Emerging Anticancer Agents
Raut, N., Vohra, S., Kaushalye, P., Mane, S., Malode, D., Umekar, M., Alhudhaibi, A. M., Chaudhary, A. A., & Trivedi, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125179
“…antigen-presenting cells (via DAMPs) and priming cytotoxic T-cells, ICD elicits a response from the innate immune system as well as an adaptive immune system to support effective total and whole integration of peptide-based immunotherapies with ICD-induced DAMP generation (Figure 1C) [42].”
Cheng, X., & Qin, Z. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05595-x
Wang, J., Lin, F., & Chen, X. (2026) · American Journal of Cancer Research · doi:10.62347/ktth2223
Yao, Y., Huang, L., Xia, R., Yuan, Y., Shen, Y. F., Zou, X., Zhao, C., Chen, C. Y., & Chen, D. (2026) · BMC Cancer · doi:10.1186/s12885-026-16513-1
“Substantial preclinical and clinical evidence indicates that the therapeutic efficacy of various effective anticancer treatments is closely linked to their ability to induce ICD in tumor cells [10].”
Women’s Special Issue Series: Biomedicines (2nd Edition)
Falà, F., Ohashi, R., & Polito, L. (2026) · Biomedicines · doi:10.3390/biomedicines14071544
Hirose, M., Kobayashi, Y., Takeda, Y., Shimogaichi, H., Tamiaki, H., Kuribara, T., & Totani, K. (2026) · Photochemistry and Photobiology · doi:10.1111/php.70134
Shi, J., Wang, Z., Zhao, Q., Liu, P., Liang, L., Chen, G., He, D., & Zhao, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1890647
Lorestani, P., Robat-Jazi, B., Nejati, N., Jazi, K., Faghihkhorasani, F., Khalili, A., Karimizadeh, Z., Kalantari, A., Mirsharifi, E., Hojjat, S. H., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05539-3
“Dual-target strategies combining VEGF/VEGFR inhibitors with PD-1/PD-L1 blockade show mixed results: high response rates in EPOC1706 [296], but no OS improvement in LEAP-015 [297], highlighting the need for better biomarker-guided selection.”
Zhang, W., Ni, X., Zhuo, L., Liu, J. Z., Yang, G., Li, J., Tang, L., Du, X., Shan, C., Feng, G., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102932
Tong, Y., Sun, K., Liu, J., & Li, F. (2026) · Molecules · doi:10.3390/molecules31152557
“At present, anti‑tumor drugs commonly used in clinics are mainly divided into three cate‑ gories: chemotherapy drugs, targeted drugs and immunotherapy drugs [8].”
Gobbini, É., Diallo, M., Clément-Duchêne, C., CHOUAID, C., Hiret, S., AUDIGIER-VALETTE, C., Bizieux, A., Debieuvre, D., Quantin, X., Guen, Y. L., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108324
“12 For example, lurbi-nectedin exerts immunomodulatory effects by depleting tumor-associated macrophages (TAMs), thereby alleviating immunosuppression within the tumor microenvironment (TME), and by activating the STING pathway, which increases interferon signaling, proinflammatory chemokines, and…”
Li, D., Hu, J., Cui, Y., Li, Q., & Li, X. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s627345 · Cited by 1
“136,137 For example, pH-sensitive cis-aconityl-DOX (CAD) and unmethylated CpG were co-encapsulated in a polycationic polyethylenimine (PEI) carrier to form the PEI/CpG/CAD nanocomplex.”
Combining chemotherapy and cold atmospheric plasma treatment: Empirical and theoretical insights
Živanić, M., Matušů, P., Ginebra, M., & Canal, C. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103508
Immunogenic cell death in CNS diseases: From bench to bedside
Li, P., Zhou, Z., Qing, Y., Wei, X., Mei, Z., & Zhang, W. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103342
Immunogenic Cell Death‐Associated miRNAs in the Tumor Microenvironment of Hepatocellular Carcinoma
Jiang, A., Mo, Y.-Q., Wang, Y., Qiu, K., Ni, Y., Ma, L., Zhang, R., Zhang, Y., 吴江锋, & Li, B. (2026) · Journal of Surgical Oncology · doi:10.1002/jso.70363
Atalay, B. R., Radeva, L., Yoncheva, K., Aydemir, E., & Ayaz, F. (2026) · Journal of Materials Science · doi:10.1007/s10853-026-13684-x
Minaei, E., Cox, D., Thind, A. S., Tincknell, G., Coleman, L. A., Wade, S. J., Islam, N., Waring, D., Ahuja, M., Malfa, J. L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.07.749769
In situ vaccination for the treatment of localized cancer and the prevention of metastatic disease
Lee, S., Kim, M., Wang, Y., Johnson, B., & You, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862956
“Clinically, chemotherapy is generally incorporated into multimodal regimens, and evidence supporting chemotherapy as a stand-alone ISV remains limited (45).”
Advances in γδ T cell-mediated immune surveillance in cervical cancer
Wang, J., Xu, X., & Li, Q. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1919105
Das, S., & Raichur, A. M. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103039
Zhou, X., Liu, Q., Yang, Z., You, T., Wang, P., Wu, C., Huang, W., & Li, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.120004
Tubertini, M., Menilli, L., Milani, C., Martini, C., Navacchia, M. L., Nugnes, M., Bartolini, M., Naldi, M., Tedesco, D., Martella, E., et al. (2024) · doi:10.3389/fchem.2024.1378233.s001
Metadata
- Authors
- Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Zhang, Zhenyong
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-21
- Volume
- 14
- Pages
- 1152934-1152934
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10160433
- OpenAlex
- W4366690216
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 38 · 2023: 6
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- immunogenic cell death, targeted therapy, HMGB1, calreticulin, ATP, heat shock proteins, tumor immunology, chemoimmunotherapy, doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, paclitaxel, antitumor immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.